Neurocrine Biosciences | NBIX - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cytokinetics USD 129.84M 7.32M 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Exelixis USD 226.15M 256.34M 2026-03
Gilead Sciences USD 7.56B 234M 2025-12
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pfizer USD 1.7B 561M 2026-03
Prothena USD 329.46M 21.93M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Repligen USD 582.65M 16.63M 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03
Xoma USD 143.9M 7.68M 2024-06